There are many issues that surround immunotherapy and immunomodulatory drugs, such as PD-1 and PD-L1 inhibitors and associated biomarkers. There is a need to develop universally accepted, standardized criteria for immunohistochemistry-based testing of immune checkpoint markers, in particular for PD-L1. According to the Pulmonary Pathology Society, “most laboratories cannot bear the burden of high‐volume send‐out testing; as a result, it is almost inevitable that predictive diagnostics for immunotherapeutics will become a distributed practice, and inter‐laboratory reproducibility will necessarily become a key element of quality assurance.” Pathologists are being asked to determine the best test to use; however, in the US, the Food and Drug Administration is basing decisions on the test used in the clinical trials and not looking in a universal fashion.
At the same time, there is rapidly evolving interest in genomic biomarkers- in particular tumor mutation burden (TMB) – that may be used in conjunction with or independent of PD-L1 status. It is critical that practicing pathologists make informed decisions about introduction of new biomarkers into their practice. Many new biomarkers have associated high costs both in the form of capital and reagent expenditures or as send out tests. It may be difficult to quickly access unbiased information and pathologists may find themselves unduly influenced by marketing campaigns or by focused and possibly impractical demands from other clinicians.
The primary goal of this guideline is to develop evidence-based recommendations for the testing of immunotherapy / immunomodulatory biomarkers including PD-L1 and TMB in patients with lung cancer. Rapid advancement in first and second-line therapy has led to the approval of immune therapies for these patients. Companion diagnostics are required for certain therapies, but there may be variability in methodology, concordance between methods and standardization.
- In non small cell lung cancer (NSCLC) patients who are being considered for immuno-oncology neoadjuvant therapy, does PD-L1 and TMB testing improve treatment response rates and survival rates?
- When selecting patients for anti-PD1 and anti-PD-L1 therapy, does testing of different specimen types provide concordant clinical outcomes?
- Does the use of immunotherapy in advanced NSCLC patients with targetable ALK, EGFR, ROS1, or BRAF molecular alterations affect their long-term clinical outcomes?
- When selecting patients for anti-PD1 and anti-PD-L1 therapy, does TMB testing have the analytical validity to identify a complementary population who will benefit from therapy?
- In NSCLC patients with more than one available sample, do multiple samples provide concordant PD-L1 and TMB testing results and downstream clinical outcomes?
- Does clinical validity of PD-L1 testing differ by levels of PD-L1 expression in tumor or immune cells?
- How reproducible are PD-L1 tumor cell scores and immune cell scores across specimen types?
- Do the available PD-L1 assays provide concordant expression profiles when evaluating the same sample and which IHC expression cut-off provides the most reproducible expression categorization across the assays?
Research and Review
Expert Panel Members
- Lynette M. Sholl, MD, FCAP, Co-chair
- Larissa V. Furtado, MD, FCAP, Co-chair
- Mark Awad, MD, PhD
- Mary Beth Beasley, MD
- Richard Cartun, MS, PhD
- David Hwang, MD, FCAP, PhD
- Gregory P. Kalemkerian, MD
- Sylvie Lantuejoul, MD, PhD
- Mari Mino-Kenudson, MD
- Ajit Paintal, MD
- Lauren Ritterhouse, MD, FCAP
- Paul Swanson, MD, FCAP
- Carol Colasacco, MLIS, SCT(ASCP)
- Kearin Reid, MLIS, MLS(ASCP)
- Lesley Souter, PhD
- Christina B. Ventura, MPH, MT(ASCP)
- American Society of Clinical Oncology
- Association for Molecular Pathology
- International Association for the Study of Lung Cancer
- Pulmonary Pathology Society
- LUNGevity Foundation
Review more upcoming CAP evidence-based guidelines by the Center.